Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial

BACKGROUND: The standard treatment regimen for drug-sensitive tuberculosis (TB), comprising four companion drugs, requires a minimum duration of 6 months, and this lengthy treatment leads to poor adherence and increased toxicity. To improve rates of adherence, reduce adverse events, and lower costs,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwak, Nakwon, Jeon, Doosoo, Park, Youngmok, Kang, Young Ae, Kim, Kyung Jong, Kim, Young Ran, Kwon, Byoung Soo, Kwon, Yong-Soo, Kim, Hyung-Jun, Lee, Jae Ho, Lee, Ji Yeon, Lee, Jung-Kyu, Mok, Jeongha, Cheon, Minkyoung, Park, Jiwon, Hahn, Seokyung, Yim, Jae-Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387084/
https://www.ncbi.nlm.nih.gov/pubmed/35978342
http://dx.doi.org/10.1186/s13063-022-06631-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387084/
https://www.ncbi.nlm.nih.gov/pubmed/35978342
http://dx.doi.org/10.1186/s13063-022-06631-z

Ejemplares similares